



Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 – HITAC Update

Shelly Spiro, Task Force Co-Chair

Hans Buitendijk, Task Force Co-Chair

October 19, 2023



Agenda

- Task Force Charge
- Task Force Membership
- Task Force Progress



Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Charge

Overarching charge: Identify recommendations to support interoperability between pharmacy constituents, and the exchange of information necessary for medication management, patient safety and consumer engagement.

Recommendations Due: November 9, 2023

Specific charge:

1. Public Health, Emergency Use Authorizations, and Prescribing Authorities

Short-term

- a. Identify critical standards and data needs for pharmacists and interested parties to participate in emergency use interventions.
- b. Are there actions ONC can take to enable data exchange in support of public health emergency use cases? For example, Test to Treat and COVID-19 treatment prescribing?

Long-term

- a. Recommendations to better integrate pharmacy systems and data for public health surveillance, reporting and public health interventions.



Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Charge (Continued)

Specific charge:

2. Identify opportunities and recommendations to improve interoperability between pharmacy constituents (prescribers, pharmacists, pharmacy benefit managers, dispensers, payers, intermediaries, PDMPs, public health agencies, HIEs, third party service providers, consumers, etc.) for pharmacy-based clinical services and care coordination.
 - a. How can ONC help facilitate adoption and use of standards to support data exchange for pharmacy-based clinical services?
 - b. Which priority pharmacy-based clinical use cases should ONC focus on in the short-term and long-term?
 - c. What technology gaps exist for pharmacists to participate in value-based care?
 - d. What can ONC do to address drug inventory transparency for prescribers and consumers?
3. Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.
 - a. What standards gaps exist for the prescribing and management of:
 - i. specialty medications
 - ii. digital therapeutics
 - iii. gene therapies
4. Identify policy and technology needs and considerations for direct-to-consumer medication services.

Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Roster



Name	Organization	Name	Organization
Hans Buitendijk* (Co-Chair)	Oracle Health	Shelly Spiro (Co-Chair)	Pharmacy HIT Collaborative
Pooja Babbrah	Point-of-Care Partners	Deven McGraw*	Invitae Corporation
Chris Blackley	Prescriptive North Dakota Health Information Network	Ketan Mehta	Micro Merchant Systems
Shila Blend*		Justin Neal	Noble Health Services Harvard Medical School & Harvard Pilgrim Health Care Institute
David Butler	Curatro, LLC Texas Department of State Health Services	Eliei Oliveira*	
Steven Eichner*	MCG Health, part of the Hearst Health network	Naresh Sundar Rajan*	CyncHealth
Rajesh Godavarthi*	Centers for Disease Control and Prevention	Scott Robertson	Bear Health Tech Consulting
Jim Jirjis**		Alexis Snyder*	Individual
Summerpal Kahlon	Rocket Health Care	Fillipe Southerland*	Yardi Systems, Inc.
Steven Lane*	Health Gorilla Department of Veterans Health Affairs	Christian Tadrus	Community Pharmacy Owner
Meg Marshall**		Sheryl Turney*	Elevance Health
Anna McCollister*	Individual	Afton Wagner	Walgreens

Four parallel blue lines of varying lengths, slanted upwards from left to right, positioned on the left side of the slide.

Task Force Progress



Completed Task Force Topics From 6/21-8/16 (August HITAC Update)

TF Topic 1: SHORT-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities

(a) Identify critical standards and data needs for pharmacists and interested parties to participate in emergency use interventions.

(b) Are there actions ONC can take to enable data exchange in support of public health emergency use cases? For example, Test to Treat and COVID-19 treatment prescribing?

TF Topic 1: LONG-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities

(a) Recommendations to better integrate pharmacy systems and data for public health surveillance, reporting and public health interventions.

TF Topic 2: Identify opportunities and recommendations to improve interoperability between pharmacy constituents for pharmacy-based clinical services and care coordination

(a) How can ONC help facilitate adoption and use of standards to support data exchange for pharmacy-based clinical services?

(b) Which priority pharmacy-based clinical use cases should ONC focus on in the short-term and long-term?

(c) What technology gaps exist for pharmacists to participate in value-based care?



Completed Task Force Topics From 8/17-10/18


<u>Meeting Date</u>	<u>Area of Focus</u>	<u>External SMEs</u>
August 23	<p><u>TF Topic 2: Identify opportunities and recommendations to improve interoperability between pharmacy constituents for pharmacy-based clinical services and care coordination</u></p> <p>(d) What can ONC do to address drug inventory transparency for prescribers and consumers?</p>	Phillip Lettrich, RPh, Health Policy and Business Development – Vela
August 30	<p><u>TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.</u></p> <p>(a) What standards gaps exist for the prescribing and management of: i. specialty medications</p>	N/A
September 13	<p><u>TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.</u></p> <p>(a) What standards gaps exist for the prescribing and management of: ii: digital therapeutics</p>	N/A

Completed Task Force Topics From 8/17-10/18 (Continued)

<u>Meeting Date</u>	<u>Area of Focus</u>	<u>External SMEs</u>
September 20	<p><u>TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.</u></p> <p>(a) What standards gaps exist for the prescribing and management of: iii: gene therapies</p>	<p>Stephanie Garcia, Branch Chief, ONC</p> <p>Mark Dunnenberger, Assistant Vice President, Personalized Medicine and Pharmacogenomics, NorthShore University Health System</p>
September 27	<p><u>TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.</u></p> <p>(a) What standards gaps exist for the prescribing and management of: iii: gene therapies</p>	<p>Ibrar Ahmed, Software and Enterprise Architecture Manager, ZS</p>
October 4	<p><u>TF Topic 4: Identify policy and technology needs and considerations for direct-to-consumer medication services.</u></p>	<p>N/A</p>



Completed Task Force Topics From 8/17-10/18 (Continued)



<u>Meeting Date</u>	<u>Area of Focus</u>	<u>External SMEs</u>
October 11	TF Topic 4: Identify policy and technology needs and considerations for direct-to-consumer medication services.	N/A
October 18	Revise and finalize Task Force recommendations	N/A



Upcoming Task Force Topics

Meeting Date

Area of Focus

October 25

Revise and finalize Task Force recommendations

November 1

Revise and finalize Task Force recommendations

November 9

Final recommendations delivered to HITAC

Use Cases

- Bi-directional access to Individual patient data supporting testing through treatment process
- Incorporate pharmacist into the care team
- Consumer Engagement
- Data-driven medication-related population level interventions
- Pharmacy Quality Measures of Clinical Pharmacy Services
- VBC Quality Measures Cross Care Team
- Public Health
- Patient Safety





Themes and Topics

- Standards and Data Exchange
- Pharmacist - Other Provider Collaboration and Data Sharing Needs
- Pharmacist - Public Health Collaboration and Data Sharing Needs
- Pharmacist - Special Settings/Populations/Long Term Care Collaboration and Data Sharing Needs
- Pharmacist Data Capture
- Information Sharing/Blocking
- Jurisdictional Variations of Standards and Rules
- Resources/Funding
- Privacy and Consent

Summary

- 38 Recommendations
- Number of recommendations per section:
 - **General** (8 recommendations)
 - **Interoperability Capabilities of Particular Interest** (14 recommendations)
 - **Patient Matching and Record Linkage** (3 recommendations)
 - **Emerging Therapies** (1 recommendations)
 - **Specialized/Focused Certification and Funding** (6 recommendations)
 - **Quality Measures** (4 recommendations)
- Each recommendations will reference the applicable Use Case(s), Topic and Theme(s) and Question(s) from the charge
 - Rationale: many recommendations address multiple Use Cases, Topics and Themes, and Questions
- One parking lot topic for future HITAC consideration
- On track to complete the recommendations by November 9, 2023





Discussion